Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Gastrointestinal tumours, colorectal 2

2037 - A Multi-Omic Analysis for Prospective Patient Stratification in Localised Colorectal Cancer (CRC).


21 Oct 2018


Poster Discussion session - Gastrointestinal tumours, colorectal 2


Translational Research

Tumour Site

Colon and Rectal Cancer


Noelia Tarazona Llavero


N. Tarazona Llavero1, E. Fontana2, V. Gambardella1, F. Gimeno-Valiente1, J. Castillo1, A. Calon3, C. Martínez-Ciarpaglini4, L. Peiró-Chova5, M. Huerta1, S. Zuñiga1, P. Rentero-Garrido1, J. Montón-Bueno1, D. Roda1, S. Roselló1, B. Bellosillo6, A. Vivancos7, G. Nyamundana2, C. Montagut3, A. Sadanandam2, A. Cervantes8

Author affiliations

  • 1 Medical Oncology, Biomedical Research Institute INCLIVA, 46010 - Valencia/ES
  • 2 Division Of Molecular Pathology, The Institute of Cancer Research, SM2 5NG - London/GB
  • 3 Medical Oncology And Cancer Research Program, Hospital del Mar-IMIM, 08003 - Barcelona/ES
  • 4 Pathology, Biomedical Research Institute INCLIVA, 46010 - Valencia/ES
  • 5 Biobanco Pt17/0015/0049, B.000768 Isciii, Biomedical Research Institute INCLIVA, 46010 - Valencia/ES
  • 6 Pathology And Cancer Research Program, Hospital del Mar-IMIM, 08003 - Barcelona/ES
  • 7 Genomics, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 8 Medical Oncology, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2037


Early stage CRC is highly heterogeneous at multiple molecular levels. However, microsatellite instability (MSI) is the only recommended biomarker to risk stratify patients (stage II). New biomarkers and clinically-applicable assays are highly necessary. These require thorough biological understanding and prospective validation for real-time application.


Stage I-III CRC patients were prospectively recruited at the INCLIVA Institute (Valencia) in collaboration with the Institute of Cancer Research (London). Clinicopathological features (such as stage, grade, sidedness, MSI, CDX2 expression, vascular/perineural invasion, Neu/Lymph ratio (NLR) and platelets/lymph (PLR)) were collected. DNA and RNA extracted from FFPE samples were assessed with a custom 29 frequently mutated CRC gene-panel (NGS) and a validated CRCAssigner/CMS subtyping assay (NanoCRC – NanoString Technologies). Plasma-based prometastatic cytokines (IL-6, IL-11, TGF-b) were measured (ELISA). Fisher’s exact test, Kruskal-Wallis and Mann Whitney tests were used for categorical/non categorical variables.


A total of 119 patients with known clinical variables were available for subtypes, mutational profile and cytokines levels analysis. NanoCRC subtypes demonstrated known significant association (p<0.05) with clinical and mutational features (CMS1 and right side, MSI high; CMS3 and RAS mutation) and newly observed significant association with CDX2 expression (low in CMS1), CTNNB1 mutation (enriched in CMS3), vascular/perineural invasion (high in mesenchymal subtypes CMS1 and 4). Between cytokines, high IL-6 levels were significantly associated (p<0.05) with CMS subtypes (high in CMS1) BRAF mutation, right sidedness, MSI status, high grade, vascular invasion, high NLR and PLR. After 18.7 months of median follow-up, disease relapse was observed in 10 patients. A multivariable analysis confirmed stage, low CDX2, vascular/perineural invasion significantly associated with relapse and borderline significance for CMS4.


LBs response-based multi-omics profiles identify diverse risk groups, predict response to adjuvant therapy and may ultimately lead to a personalised approach for early CRC.

Clinical trial identification

Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.